ACTION: Notice of application.

SUMMARY: Cambrex Charles City has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2021. Such persons may also file a written request for a hearing on the application on or before August 23, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on May 6, 2021, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616–3466, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric		
Acid	2010	1
Tetrahydrocannabinols	7370	I
Amphetamine	1100	Ш
Lisdexamfetamine	1205	II
Methylphenidate	1724	II
ANPP (4-Anilino-N-		
phenethyl-4-piperidine)	8333	II
Phenylacetone	8501	II
Codeine	9050	II
Oxycodone	9143	Ш
Hydromorphone	9150	Ш
Hydrocodone	9193	Ш
Methadone	9250	11
Morphine	9300	11
Oripavine	9330	11
Thebaine	9333	11
Opium extracts	9610	11
Opium fluid extract	9620	11
Opium tincture	9630	11
Opium, powdered	9639	11
Oxymorphone	9652	11
Noroxymorphone	9668	II
Fentanyl	9801	II

The company plans to manufacture the above-listed controlled substances in bulk for conversion to other controlled substances and sales to its customers for dosage form development, clinical trials and use in stability qualification studies. In reference to drug code 7370

(Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activities for these drug codes are authorized for this registration.

William T. McDermott,

Assistant Administrator. [FR Doc. 2021–13252 Filed 6–23–21; 8:45 am] BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-858]

Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Annac Medical Center LC

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW 8701 Morrissette Drive, Springfield, Virginia 22152. To ensure proper handling of comments, please reference Docket No—DEA–858 in all correspondence, including attachments.

SUPPLEMENTARY INFORMATION: The Controlled Substances Act (CSA) prohibits the cultivation and distribution of marihuana except by persons who are registered under the CSA to do so for lawful purposes. In accordance with the purposes specified in 21 CFR 1301.33(a), DEA is providing notice that the entity identified below has applied for registration as a bulk manufacturer of schedule I controlled substances. In response, registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections of the requested registration, as provided in this notice. This notice does not constitute any evaluation or

determination of the merits of the application submitted.

The applicant plans to manufacture bulk active pharmaceutical ingredients (APIs) for product development and distribution to DEA registered researchers. If the application for registration is granted, the registrant would not be authorized to conduct other activity under this registration aside from those coincident activities specifically authorized by DEA regulations. DEA will evaluate the application for registration as a bulk manufacturer for compliance with all applicable laws, treaties, and regulations and to ensure adequate safeguards against diversion are in place.

As this applicant has applied to become registered as a bulk manufacturer of marihuana, the application will be evaluated under the criteria of 21 U.S.C. 823(a). In addition to seeking to produce marihuana extract, this applicant is separately seeking to cultivate marihuana. See Notice of Application, Bulk Manufacturers of Marihuana, 84 FR 44920, 44922 (Aug. 27, 2019). DEA will conduct this evaluation in the manner described in the rule published at 85 FR 82333 on December 18, 2020, and reflected in DEA regulations at 21 CFR part 1318.

In accordance with 21 CFR 1301.33(a), DEA is providing notice that on April 14, 2021, Annac Medical Center, LC, 5172 West Patrick Lane, Suite 100, Las Vegas, Nevada 89117– 8911, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols	7370	I

William T. McDermott,

Assistant Administrator. [FR Doc. 2021–13249 Filed 6–23–21; 8:45 am] BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Oil Pollution Act

On June 17, 2021, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Western District of Louisiana in the lawsuit entitled *United States of America and Louisiana* v. *CITGO Petroleum Corp.,* Civil Action No. 2:21–cv–1705. The United States is

acting at the request of the designated federal trustees: National Oceanic and Atmospheric Administration ("NOAA") and the United States Department of the Interior ("DOI") through the United States Fish and Wildlife Service. The State of Louisiana is acting through its designated State trustees: The Louisiana Oil Spill Coordinator's Office, Department of Public Safety & Corrections ("LOSCO"), Louisiana Department of Natural Resources ("LDNR"), Louisiana Department of Environmental Quality ("LDEQ"), Louisiana Department of Wildlife and Fisheries ("LDWF"), and the Coastal Protection and Restoration Authority 'CPRA'').

This is a civil action brought against Defendant CITGO Petroleum Corp. for recovery of damages for injury to, destruction of, loss of, or loss of use of natural resources, under Section 1002 of the Oil Pollution Act ("OPA"), 33 U.S.C. 2702, and Section 2480 of the Louisiana Oil Spill Prevention and Response Act ("OSPRA"), La. Rev. Stat. 30:2480. The United States and Louisiana seek damages in order to compensate for and restore natural resources injured by CITGO's oil discharge that occurred at CITGO refinery in Lake Charles, Louisiana, beginning on or about June 18, 2006. The United States and the State also seek to recover unreimbursed costs of assessing such injuries.

The Complaint in this natural resource damages case was filed against CITGO concurrently with the lodging of the proposed Consent Decree. The Complaint alleges that CITGO is liable for damages under OPA and OSPRA. The Complaint alleges that CITGO discharged oil into the Indian Marais waterway, the Calcasieu River, and the Calcasieu Estuary in June 2006 and that natural resources were injured as a result of the discharge.

Under the proposed Consent Decree, CITGO will pay a total of \$19,688,149.83. Of this total, CITGO will pay \$19.16 million to the trustees to restore, replace, or acquire the equivalent of the natural resources allegedly injured, destroyed, or lost as a result of the oil spill and \$528,149.83 to reimburse the trustees for all remaining unpaid assessment costs.

The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Acting Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States of America and Louisiana* v. *CITGO Petroleum Corp.*, D.J. Ref. No. 90–5–1–1–09112/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted by either email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@ usdoj.gov.
By mail	Acting Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Wash- ington, DC 20044–7611.

During the public comment period, the proposed Consent Decree may be examined and downloaded at this Justice Department website: *https:// www.justice.gov/enrd/consent-decrees.* We will provide a paper copy of the proposed Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$7.75 (25 cents per page reproduction cost) payable to the United States Treasury.

Thomas Carroll,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2021–13449 Filed 6–23–21; 8:45 am] BILLING CODE 4410–15–P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

[Application Number D-11681]

RIN 1210-ZA18

Reopening of Comment Period for Proposed Amendments to Class Prohibited Transaction Exemptions To Remove Credit Ratings Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act

AGENCY: Employee Benefits Security Administration, Department of Labor. **ACTION:** Notice of reopening of comment period.

SUMMARY: The Department of Labor is reopening the comment period on proposed amendments to six class exemptions from prohibited transaction rules set forth in the Employee Retirement Income Security Act of 1974 (ERISA) and the Internal Revenue Code (the Code). The exemptions are Prohibited Transaction Exemptions (PTEs) 75–1, 80–83, 81–8, 95–60, 97–41 and 2006–16. The proposed amendments relate to the use of credit

ratings in the conditions of these class exemptions. Section 939A of the Dodd-Frank Wall Street Reform and Consumer Protection Act requires the Department to remove any references to or requirements of reliance on credit ratings from its class exemptions and to substitute standards of creditworthiness as the Department determines to be appropriate. This reopening of the comment period provides interested persons with the opportunity to submit additional comments on the proposed amendments due to the passage of time since the proposal was originally published in 2013. All comments received to date on the proposed amendments will be included in the public record and need not be resubmitted. The proposed amendments to the class exemptions would affect participants and beneficiaries of employee benefit plans and IRAs, fiduciaries of the plans and IRAs, and financial institutions that engage in transactions with, or provide services to, the plans and IRAs.

DATES: The Department is reopening the comment period for proposed amendments to certain class exemptions that were published in the Federal Register on June 21, 2013 (78 FR 37572). Written comments and requests for a public hearing must be received by the Department on or before August 9, 2021. If the Department adopts final amendments, they would be effective 180 days after the date of their publication in the Federal Register.

ADDRESSES: All written comments and requests for a public hearing concerning the proposed amendments should be sent to the Employee Benefits Security Administration, Office of Exemption Determinations, U.S. Department of Labor through the Federal eRulemaking Portal and identified by Application No. D–11681:

Federal eRulemaking Portal: http:// www.regulations.gov at Docket ID number: EBSA 2012–0013 (follow the instructions for submitting comments).

Warning: All comments received will be included in the public record without change and will be made available online at http:// www.regulations.gov, including any personal information provided, unless the comment includes information claimed to be confidential or other information whose disclosure is restricted by statute. If you submit a comment, EBSA recommends that you include your name and other contact information, but DO NOT submit information that you consider to be confidential, or otherwise protected (such as Social Security number or an